BIGG Rec Logo
BIGG Rec Logo

Bibliographic Info

GuidelineRecommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB- and HIV-prevalence settings – 2015 update
Year of Publication2015
Issuing InstitutionWorld Health Organization

Recommendation

Status
Maintained

Recommended in favor

Conditional

In resource-constrained settings with high TB incidence and transmission, adults and adolescents living with HIV, who have an unknown or positive tuberculin skin test (TST) status and among whom active TB disease has been safely ruled out, should receive at least 36 months of isoniazid preventive therapy (IPT). IPT should be given to such individuals regardless of whether or not they are receiving ART. IPT should also be given irrespective of the degree of immunosuppression, history of previous TB treatment, and pregnancy

Notes and Remarks

People living with HIV in high TB incidence and transmission settings, regardless of their TST status, benefit more from IPT of 36 months or longer, compared to six-month IPT, with greater protective benefit in those with a positive TST. There is a significant additional benefit from longer-term IPT for those receiving ART. TST is encouraged whenever feasible, but it is not a pre-requisite for IPT. If TST is performed, those with a negative TST should not receive 36 months of IPT. Settings with high TB incidence and transmission should be defined by national authorities, taking into consideration the local epidemiology and transmission of both TB and HIV.

Also Featured In

This recommendation also appears in the following guidelines:

Originally Developed
Guideline

WHO policy on collaborative TB/HIV activities : guidelines for national programmes and other stakeholders

Year2012
InstitutionWHO
Guideline

Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings

Year2011
InstitutionWorld Health Organization
Guideline

Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach

Year2016
InstitutionWHO
Guideline

Latent tuberculosis infection: updated and consolidated guidelines for programmatic management

Year2018
InstitutionWHO
Guideline

WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: Module 1: prevention

Year2020
InstitutionWHO
Guideline

Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach

Year2021
InstitutionWHO
Guideline

WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents.

Year2022
InstitutionWHO
Guideline

WHO consolidated guidelines on tuberculosis: module 6: tuberculosis and comorbidities.

Year2024
InstitutionWorld Health Organization
Guideline

WHO consolidated guidelines on tuberculosis: module 6: tuberculosis and comorbidities, 2nd ed.

Year2025
InstitutionWorld Health Organization
Powered byEpistemonikos Foundation